

STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Bill J. Crouch Cabinet Secretary Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Cynthia E. Beane Commissioner

Pharmaceutical and Therapeutics Committee

August 25th, 2021

Location: WebEx only
Time: Executive Session 2:30 PM – 3:30 PM
Time: Open Session 3:30 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

MINUTES

Committee Members Present:

Chris Terpening, PharmD, PhD, Vice-Chair
Philip Galapon, MD FAAFP, Chair
Bradley Henry, MD
David Gloss, MD
John Bernabei, RPh
Charles Rohrbaugh, RPh
Kelli Lynn Jennings, PharmD

Absent:

Tom Kines, RPH Toni DiChiacchio, DNP

Division of Medicaid Staff Present:

Bill Hopkins, Operations Manager Priya Shah, PharmD, DUR Coordinator Doug Sorvig, Data Analyst Brian Thompson, PharmD, MS, Director Gail Goodnight, RPH Rebate Pharmacist Lori Moles, RPH Pharmacist

Contract Staff Present:

Change Healthcare
Ryan Fell, PharmD
Jacquelyn Hedlund, MD
Steve Liles, PharmD

Other Contract / State Staff Present:

I. Call to Order

Philip Galapon, Chairman, called the meeting to order at 3:32 PM

II. Welcome and Introductions

Philip Galapon welcomed all present to the committee meeting. Committee members, Bureau of Medical Services staff, and Change Healthcare staff introduced themselves.

III. Housekeeping Items / Updates

A. Approval of the April 28th Meeting Minutes

The Committee moved to approve the April 28th, 2021 Meeting Minutes. All were in favor with no objections or revisions.

B. PDL Compliance / Generic Percent Report Updates

Ryan Fell provided an explanation of the PDL Compliance and Generic Percent reports.

- Ryan Fell reviewed the Generic Percent Report; overall generic utilization for Q1 2021 was 83.3%
- Ryan Fell reviewed the PDL Compliance Report; overall compliance for Q1 2021 was 92.6%

IV. Public Comments

Public comments for this meeting were only accepted in writing. Written statements were provided to State and Committee members for review prior to this meeting and are available to the public on the State's website.

V. New Business

A. New Drug Reviews

i. Analgesics, Narcotic Short Acting

ANALGESICS, NARCOTIC SHORT ACTING (Non-parenteral) APP

CLASS PA CRITERIA: Non-preferred agents require six (6) day trials of at least four (4) chemically distinct preferred agents (based on the narcotic ingredient only), including the generic formulation of the requested non-preferred agent, before they will be approved, unless one (1) of the exceptions on the PA form is present.

NOTE: All tramadol and codeine products require a prior authorization for children under 18 years of age. Requests must be for an FDA approved age and indication and specify non-opioid therapies attempted.

APAP/codeine butalbital/APAP/caffeine/codeine

hydrocodone/APAP 2.5/325 mg, 5/325 mg, 7.5/325 mg,10/325 mg

hydrocodone/APAP solution hydrocodone/ibuprofen hydromorphone tablets LORTAB SOLUTION

(hydrocodone/acetaminophen)

morphine oxycodone tablets, concentrate, solution

oxycodone/APAP oxycodone/ASA

pentazocine/naloxone tramadol

tramadol/APAP

ABSTRAL (fentanyl) ACTIQ (fentanyl) butalbital/ASA/caffeii

butalbital/ASA/caffeine/codeine butorphanol

DEMEROL (meperidine) dihydrocodeine/ APAP/caffeine

DILAUDID (hydromorphone) fentanyl

FENTORA (fentanyl) FIORICET W/ CODEINE

(butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE

(butalbital/ASA/caffeine/codeine) hydrocodone/APAP 5/300 mg, 7.5/300 mg, 10/300 mg

hydromorphone liquid, suppositories levorphanol

LORCET (hydrocodone/APAP) LORTAB (hydrocodone/APAP)

meperidine
NORCO (hydrocodone/APAP)
NUCYNTA (tapentadol)

oxycodone capsules oxycodone/ibuprofen oxymorphone

PERCOCET (oxycodone/APAP)

QDOLO SOLUTION (tramado ROXICODONE (oxycodone)

ULTRACET (tramadol/APAP)
VICOPROFEN (hydrocodone/ibuprofen)

Fentanyl buccal, nasal and sublingual products will only be authorized for a diagnosis of cancer and as an adjunct to a long-acting agent. These dosage forms will not be authorized for monotherapy.

Limits: Unless the patient has escalating cancer pain or another diagnosis supporting increased quantities of short-acting opioids, all short acting solid forms of the narcotic analgesics are limited to 120 tablets per thirty (30) days. Longer-acting medications should be maximized to prevent unnecessary breakthrough pain in chronic pain therapy.

Immediate-release tramadol is limited to 240 tablets per thirty (30) days.

Charlie Rohrbaugh made a motion to approve the changes to the Analgesics, Narcotic Short Acting class as recommended; the motion was seconded by Chris Terpening and Kelli Jennings. All members were in favor and the motion was approved.


ii.Anticonvulsants

ANTICONVULSANTS

CLASS PA CRITERIA: For a diagnosis of seizure disorder, non-preferred agents require a fourteen (14) day trial of a preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present; patients currently on established therapies shall be grandfathered.

For all other diagnoses, non-preferred agents require a thirty (30) day trial of a preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.

In situations where AB-rated generic equivalent products are available, "Brand Medically Necessary" must be hand-written by the prescriber on the prescription for the brand name product to be reimbursed.



Chris Terpening made a motion to approve the changes to the Anticonvulsants class as recommended; the motion was seconded by Kelli Jennings. All members were in favor and the motion was approved.


iii.Bladder Relaxant Preparations

BLADDER RELAXANT PREPARATIONS^{AP}

CLASS PA CRITERIA: Non-preferred agents require thirty (30) day trials of each chemically distinct preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present

GELNIQUE (oxybutynin) oxybutynin IR oxybutynin ER solifenacin TOVIAZ (fesoterodine) darifenacin ER tablet
DETROL (tolterodine)
DITROPAN XL (oxybutynin)
ENABLEX (darifenacin)
flavoxate
GEMTESA (vibegron)
MYRBETRIQ (mirabegron)
OXYTROL (oxybutynin)
tolterodine
tolterodine ER
trospium
trospium ER
VESICARE (solifenacin)

Charlie Rohrbaugh made a motion to approve the changes to the Bladder Relaxant Preparations class as recommended; the motion was seconded by Chris Terpening. All members were in favor and the motion was approved.



Charlie Rohrbaugh made a motion to approve the changes to the Multiple Sclerosis Agents as recommended; the motion was seconded by Chris Terpening. All members were in favor and the motion was approved. Dr. Hedlund reviewed the guideline updates for the Multiple Sclerosis Agents class and noted the availability of HCPCS billed products for patient's who align with new guideline recommendations.



Chris Terpening made a motion to approve the changes to the Pituitary Suppressive Agents, LHRH class as recommended; the motion was seconded by Kelli Jennings. All members were in favor and the motion was approved. Chris Terpening brought an amendment to bring Oriahnn and Orilissa to preferred provisional upon the WV DUR board agreeing to make changes to the PA criteria. Chris Terpening made a motion to approve the changes; the motion was seconded by Kelli Jennings. All members were in favor and the amendment was approved.

vi.Stimulants and Related Agents


STIMULANTS AND RELATED AGENTS

CLASS PA CRITERIA: A PA is required for adults eighteen (18) years of age or older.

Non-preferred agents require a thirty (30) day trial of at least one preferred agent in the same subclass and with a similar duration of effect and mechanism of action, unless one (1) of the exceptions on the PA form is present. NOTE: Non-preferred agents will NOT be "grandfathered" for adults. Children under the age of 18 may continue their current therapy until the end of the school year after which they will be required to switch to a preferred agent.

before initiation of therapy and be established on a reliable method of contraception if appropriate and Patient is between eighteen (18) up to sixty-five (65)

years of age and



Chris Terpening made a motion to approve the changes to the Stimulants and Related Agents class as recommended; the motion was seconded by Charlie Rohrbaugh. All members were in favor and the motion was approved.

VI. Old Business

There was no old business discussed at this time.

VII. Other Business

There was no other business discussed at this time.

VIII. Next Meeting

The next P&T Committee Meeting is scheduled for October 27th, 2021, from 9:00 AM-5:00 PM, Virtual Meeting.

IX. Adjournment

The committee adjourned the meeting at 4:05 PM.